Here is our updated quick-access guide to the KEYNOTE trials investigating the anti-PD-1 agent pembrolizumab in the non-small-cell and small-cell lung cancer settings.
Prebiopsy multiparametric magnetic resonance imaging plus targeted biopsy is associated with increased detection of clinically significant prostate cancer versus ultrasonography-guided systematic biopsy alone, study data show.
Brain metastases are a common complication of lung cancer and are associated with significant morbidity and mortality. In this video, Manmeet Ahluwalia provides a neuro-oncologist's perspective on managing lung cancer patients who develop these metastases.
These videos were made possible by independent educational funding provided by AstraZeneca.
Phase II study data suggest favorable treatment response and survival with first-line gemcitabine–eribulin in cisplatin-ineligible patients with metastatic urothelial carcinoma.
Pooled long-term results from two multicenter phase II studies indicate that nivolumab is efficacious in Japanese patients with previously treated, stage IIIB/IV squamous or nonsquamous non-small-cell lung cancer.
Prebiopsy multiparametric magnetic resonance imaging plus targeted biopsy is associated with increased detection of clinically significant prostate cancer versus ultrasonography-guided systematic biopsy alone, study data show.
A French database analysis lends further support for the use immune checkpoint inhibitors for cancer in patients with pre-existing autoimmune disease.
Meet the Editorial Board
Our international Editorial Board members Dr Fiona Blackhall (Christie Hospital, Manchester, UK) and Dr Axel Merseburger (University Hospital Schleswig-Holstein, Germany) work closely with the editorial team to highlight gaps in coverage and select topics to feature on this digital platform.
Why register? Medicine Matters oncology is a free resource providing the latest news and clinical guidance
Register today and receive updates directly to your inbox! Medicine Matters oncology has been specifically developed for the time-limited healthcare professional who is looking for a single resource providing credible information on current practice and the latest advances in oncology. Already registered? Log in now to unlock your access.
